Chinese shipping giant COSCO may join the high-profile sale of Hong Kong conglomerate CK Hutchison’s global ports portfolio, a move that could intensify U.S.-China maritime rivalry. The $15 billion deal, announced on March 4, involves selling 43 ports across 23 countries—including two along the Panama Canal—to a consortium led by BlackRock (NYSE: BLK) and MSC, Italy’s largest shipping company.
Beijing has pressured CK Hutchison to include a Chinese investor after criticizing the original deal as a threat to national interests. Sources confirm COSCO is being considered, though its stake size remains under negotiation, with BlackRock and MSC preferring it as a minority partner.
The transaction faces scrutiny from nearly 50 jurisdictions and could take over two years to complete. Analysts say U.S. authorities, particularly under President Donald Trump, may oppose COSCO’s involvement due to national security concerns, especially regarding Panama Canal assets that handle over 40% of U.S. container traffic worth $270 billion annually.
JPMorgan notes COSCO’s participation could ease Chinese regulatory hurdles but warns not all ports may be included. The Panama ports are expected to be a flashpoint for Washington, with potential removal from the deal to meet U.S. strategic demands.
Experts view COSCO’s entry as a significant assertion of China’s maritime influence. “Beijing’s disapproval clearly forced Hutchison to rethink the structure,” said Isaac Kardon of the Carnegie Endowment. China’s Foreign Ministry emphasized safeguarding sovereignty and market fairness while signaling possible countermeasures if Washington intervenes.
With global trade tensions escalating, this ports sale highlights the struggle for control over critical shipping lanes and the geopolitical stakes of maritime infrastructure ownership.


Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



